| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||||||||
Net loss | ||||||||||||
-109,021 | -125,533 | -130,284 | -152,757 | -157,602 | -128,711 | -129,944 | -95,992 | -97,710 | -131,396 | 0 | 0 | 0 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||
Depreciation and amortization | ||||||||||||
4,024 | 3,817 | 3,653 | 3,411 | 3,280 | 3,269 | 3,512 | 3,674 | 3,725 | 3,673 | 0 | 0 | 0 |
Stock-based compensation expense | ||||||||||||
10,368 | 9,885 | 9,575 | 9,842 | 10,088 | 11,011 | 11,540 | 12,015 | 15,147 | 14,591 | 0 | 0 | 0 |
Loss on derivative liability | ||||||||||||
- | - | - | - | - | - | - | - | - | -15,411 | 0 | 0 | 0 |
Amortization of debt discount | ||||||||||||
1,025 | 1,026 | 0 | 0 | 0 | - | - | - | - | 3,349 | 0 | 0 | 0 |
Deferred rent expense | ||||||||||||
- | - | - | - | - | 262 | 1,825 | 1,602 | 480 | 856 | 0 | 0 | 0 |
Gain on disposal of assets | ||||||||||||
- | - | - | - | - | - | - | 0 | 0 | - | - | - | - |
Loss on disposal of assets and impairment charges | ||||||||||||
0 | - | - | - | - | - | - | - | - | -80 | 0 | 0 | 0 |
Research and development license fees settled with convertible bond and stock | ||||||||||||
- | - | - | - | - | - | - | - | - | 13,250 | 0 | 0 | 0 |
Deferred income taxes | ||||||||||||
48 | 486 | 437 | 416 | 442 | -365 | -535 | -514 | -556 | -327 | 0 | 0 | 0 |
Changes in operating assets and liabilities: | ||||||||||||
Receivables, net | ||||||||||||
30,842 | 3,738 | 10,097 | 4,426 | 12,730 | 4,483 | 612 | 1,355 | 5,912 | 5,691 | 0 | 0 | 0 |
Prepaid expenses and other assets | ||||||||||||
-16,523 | -864 | 24,762 | 35,017 | 26,371 | 13,966 | 8,105 | 7,972 | 2,613 | 4,537 | 0 | 0 | 0 |
Inventories | ||||||||||||
10,541 | 3,844 | 3,220 | 5,436 | 6,620 | 12,226 | 13,596 | 12,543 | 11,736 | 12,321 | 0 | 0 | 0 |
Accounts payable and accrued expenses | ||||||||||||
7,977 | 19,345 | 45,023 | 44,026 | 27,173 | 3,527 | 12,273 | 22,991 | 3,106 | 18,791 | 0 | 0 | 0 |
Net cash used in operating activities | ||||||||||||
-110,034 | -97,460 | -108,192 | -109,131 | -129,632 | -109,387 | -93,183 | -70,738 | -73,485 | -81,512 | 0 | 0 | 0 |
Purchase of property and equipment | ||||||||||||
14,390 | 13,572 | 9,333 | 6,577 | 3,062 | 3,321 | 3,557 | 3,633 | 5,063 | 5,440 | 0 | 0 | 0 |
Payments for licenses | ||||||||||||
64 | 4,175 | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
Purchases of short-term investments | ||||||||||||
0 | - | - | - | - | 113,259 | 110,605 | 93,170 | 119,487 | 55,282 | 0 | 0 | 0 |
Sales and maturities of short-term investments | ||||||||||||
0 | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
Sale of short-term investments | ||||||||||||
- | - | - | - | - | - | - | - | 55,149 | 52,144 | 0 | 0 | 0 |
Net cash (used in) provided by investing activities | ||||||||||||
-55,150 | 7,499 | 34,750 | 12,354 | 60,035 | -48,963 | -44,121 | -40,034 | -70,841 | -10,018 | 0 | 0 | 0 |
Cash flows from financing activities: | ||||||||||||
Proceeds from sale of stock | ||||||||||||
- | - | - | - | - | 123,134 | 0 | 0 | 0 | - | - | - | - |
Proceeds from issuance of convertible bonds | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 0 | 0 |
Proceeds from issuance of debt | ||||||||||||
6,156 | 6,464 | 0 | 0 | 0 | - | - | - | - | - | - | - | - |
Costs incurred related to the sale of stock | ||||||||||||
- | - | - | - | - | 5,518 | 5,118 | 5,735 | 14,149 | 10,168 | 0 | 0 | 0 |
Proceeds from exercise of stock options | ||||||||||||
2,049 | 1,983 | 2,400 | 3,234 | 2,971 | 3,956 | 4,030 | 3,398 | 3,498 | 2,278 | 0 | 0 | 0 |
Investment from non-controlling interest | ||||||||||||
- | - | - | - | - | - | - | - | - | 49 | 0 | 0 | 0 |
Repayment of finance lease obligations and long-term debt | ||||||||||||
974 | 972 | 129 | 136 | 252 | 544 | 818 | 1,125 | 1,239 | 1,163 | 0 | 0 | 0 |
Net cash provided by financing activities | ||||||||||||
167,208 | 167,452 | 108,722 | 204,634 | 101,030 | 169,035 | 169,167 | 69,204 | 156,676 | 96,896 | 0 | 0 | 0 |
Net (decrease) increase in cash and cash equivalents | ||||||||||||
2,024 | 77,491 | 35,280 | 107,857 | 31,433 | 10,685 | 31,863 | -41,568 | 12,350 | 5,366 | 0 | 0 | 0 |
Effect of exchange rate changes on cash and cash equivalents | ||||||||||||
-1,044 | 389 | 517 | 273 | 353 | -175 | -17 | 486 | 833 | 793 | 0 | 0 | 0 |
Supplemental cash flow disclosures | ||||||||||||
Interest paid | ||||||||||||
5,334 | 4,925 | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - |
Non-cash investing and financing activities: | ||||||||||||
Accrued purchases of property and equipment | ||||||||||||
858 | 483 | 1,001 | 1,381 | 870 | 340 | 451 | 209 | -820 | 156 | 0 | 0 | 0 |
Accrued purchases of licenses | ||||||||||||
0 | - | - | - | - | - | - | - | - | - | - | - | - |
ROU assets derecognized from modification of operating lease obligations | ||||||||||||
0 | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of equity raise in accounts payable and accrued expenses | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | 0 | 0 |
Accrued purchases of pharmaceutical licenses | ||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 0 |
Convertible bond issued in lieu of licensing cash payment | ||||||||||||
- | - | - | - | - | - | - | - | - | 7,000 | 0 | 0 | 0 |
ROU assets recognized in exchange for operating lease obligations | ||||||||||||
0 | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - |